Medicare Technical Corrections Legislation Doubtful After Rx Bill Passage
This article was originally published in The Gray Sheet
The resolve of House Republican leaders to avoid re-opening the controversial Medicare law with a technical corrections bill in 2004 will limit DME competitive bidding opponents' options in repealing the provision
You may also be interested in...
Device advocacy groups credit a maturing industry presence on Capitol Hill, reflected by CEO-level participation, with achieving relevant Medicare reforms and a focus on FDA accountability
CMS' growing emphasis on evidence-based medicine to inform reimbursement decisions increasingly will lead manufacturers to conduct "high-quality" clinical trials, according to Chief Medical Officer Sean Tunis
Johnson & Johnson/Cordis' efforts to raise the drug-eluting stent inpatient payment rates fell short in 2003, paving the way for the Cypher manufacturer and imminent competitor Boston Scientific (Taxus) to wage a concerted lobbying campaign this year